Table 4 Risk of headache with 5-HT3 receptor antagonists
From: Treatment of established postoperative nausea and vomiting: a quantitative systematic review
| Number with | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT3 receptor antagonist (mg) | Event rate | Relative risk | References | |||||||
| headache/Total number | ||||||||||
| Dose | Dolasetron | Granisetron | Tropisetron | Ondansetron | Active | Placebo | Active | Placebo | 95% confidence interval | |
| Low: | 12.5 | 0.1 | 0.5 | 1 | 7.7% | 10.4% | 41/531 | 55/531 | 0.75 (0.51 to 1.10) | [16][19][34][40][41] |
| Medium: | 25, 50 | 1 | 2 | 4 | 9.3% | 9.3% | 71/765 | 55/591 | 1.09 (0.78 to 1.52) | [16][19][34][40][41][45] |
| High: | 100 | 3 | 5 | 8 | 13.3% | 9.9% | 74/556 | 56/567 | 1.36 (0.98 to 1.88) | [16][19][34][40][41][42] |